Osteoporosis

  1. Valero, M. Llavero
  2. Vaamonde, J. Gargallo
  3. Martínez, S. Botella
  4. de la Higuera López-Frías, M.
Journal:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Year of publication: 2018

Series: 12

Issue: 69

Pages: 4062-4074

Type: Article

DOI: 10.1016/J.MED.2018.11.023 DIALNET GOOGLE SCHOLAR

More publications in: Medicine: Programa de Formación Médica Continuada Acreditado

Abstract

Osteoporosis is a chronic metabolic bone disease resulting in an increased risk of skeletal fractures due to a reduction in the density of bone tissue. It has multifactorial etiology. Since low bone density is asymptomatic, the only clinical sign of osteoporosis is the skeletal fractures. Fractures of the hip, of the vertebrae, distal forearm (Colles fracture) and proximal humerus are the most typical osteoporotic fractures. Diagnosis criteria of osteoporosis are fragility fractures and a spine or hip BMD (bone mass density), measured by dual X-ray absorptiometry (DXA), with a T-score of ≤ −2.5 SD. Treatment goal is to prevent osteoporotic fractures. Bisphosphonates continue to be the treatment of choice in osteoporosis. Nevertheless, new therapies are currently available.

Bibliographic References

  • De la Higuera López-Frías M, Fernández García D, Muñoz-Torres M. Densitometría ósea: usos clínicos y evidencia científica. Rev Clin Esp. 2004;204(9):480-2.
  • Muñoz-Torres M, de la Higuera M, Fernández-García D, Alonso G, Reyes R. Densitometría ósea: indicaciones e interpretación. Endocrinología y Nutrición. 2005;52(5):224-7.
  • Rozas Moreno P, Reyes García R, Muñoz-Torres M. Osteoporosis primaria. Capítulo 52. Madrid: SEEN; 2015.
  • Manolagas SC. Pathogenesis of osteoporosis. UpToDate 2014.
  • Teitelbaum SL. Bone resorption by osteoclasts. Science. 2000;289:1504-8.
  • Riggs BL. The mechanisms of estrogen regulation of bone resorption. J Clin Invest. 2000;106(10);1203-4.
  • Riggs BL, Khosla S, Melton JL. Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev. 2002;23:279-302.
  • Mezquita-Raya P, de la Higuera M, García DF, Alonso G, Ruiz-Requena ME, de Dios Luna J. The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women. Osteoporosis Int. 2005;16(11):1368-74.
  • González-Macías J, Pino-Montes J, Olmos JM, Nogués X. Guías de práctica clínica en la osteoporosis posmenopáusica, glucocorticoidea y del varón. Sociedad Española de Investigación Ósea y del Metabolismo Mineral (3ª versión actualizada 2014). Rev Clin Esp. 2015;215(9):479-542.
  • Martín AR, Sornay-Rendu E, Chandle JM, Duboeuf F, Girman CJ, Delmas PD. The impact of osteoporosis on quality of life: the OFELY cohort. Bone. 2002;31(1):32-6.
  • Kanis JA, MrCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster JY. Osteoporosis Int. 2013;24 (1):23-57.
  • Silva BC, Leslie WD, Resch H, Lamy O, Lesnyak O, Binkley N. Trabecular bone score: a noninvasive method based upon the DXA image. J Bone Miner Res. 2014;29:518-30.
  • Kanis JA, Harvey NC, Cooper C, Johansson H, Odén A, McCloskey EV. A systematic review of intervention thresholds based on FRAX. Arch Osteoporos. 2016:11:25.
  • Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster J-Y. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2013;24(1):23-57.
  • Cosman F, Beur SJ, De Leboff MS, Lewiecki EM, Tanner B, Randall S. Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014;25(10):2359-81.
  • Marques EA, Mota J, Carvalho J. Exercise effects on bone mineral density in older adults: a meta-analysis of randomized controlled trials. Age (Dordr). 2012;34(6):1493-515.
  • Zou L, Wang C, Chen K, Shu Y, Chen X, Luo L. The effect of taichi practice on attenuating bone mineral density loss : a systematic review and meta-analysis of randomized controlled trials. Int J Environ Res Public Health. 2017;14(9).
  • Agostini D, Zeppa Donati S, Lucertini F, Annibalini G, Gervasi M, Ferri Marini C. Muscle and bone health in postmenopausal women : role of protein and vitamin D supplementation. Nutrients. 2018;10(8).
  • Deutz NE, Bauer JM, Baarazzoni R, Biolo G, Boirie Y, Bosy-Westphal A. Protein intake and exercise for optimal muscle function with aging: recommendations from the ESPEN Expert Group. Clin Nutr. 2014;33(6): 929-3.
  • Avenell A, Wj G, Ld G, Connell OD. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and postmenopausal osteoporosis. Cochrane Database Syst Rev. 2005;(3):CD000227.
  • Eastell R, O’Neill TW, Hofbauer LC, Langdahl B, Reid IR, Gold DT. Postmenopausal osteoporosis. Nat Rev Dis Primers. 2016;2:16069.
  • Khosla S, Bilezikian JP, Dempster DW, Lewiecki EM, Miller PD, Neer RM. Benefits and risks of bisphosphonate therapy for osteoporosis. J Clin Endocrinol Metab. 2012;97:2272-82.
  • Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD, Cheung AM. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2014;29:1-23, 25.
  • Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O’Ryan F. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res. 2015;30:3-23.
  • Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361: 756-65.
  • Papapoulos S, Lippuner K, Roux C, Lin CJ, Kendler DL, Lewiecki EM. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study. Osteoporos Int. 2015;26:2773-83.
  • Silverman SL, Christiansen C, Genant HK, Vukicevic S, Zanchetta JR, de Villiers TJ. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3 year, randomized, placebo and active controlled clinical trial. J Bone Miner Res. 2008;23:1923-34.
  • Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med.2001;344:1434-41.
  • Kendler DL, Marin F, Zerbini CAF, Russo LA, Greenspan SL, Zikan V. Effects of teriparatide and risedronate on new fractures in postmenopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2018;391(10117):230-40.
  • Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J, Hansen KE. 2017 American College of Rheumatology Guideline for the prevention and treatment of glucocorticoid induced osteoporosis. Arthritis Rheum. 2017;69(8):1521-37.
  • Kothawala P, Badamgarav E, Ryu S, Miller RM, Halbert RJ. Systematic review and meta-analysis of real world adherence to drug therapy for osteoporosis. Mayo Clin Proc. 2007;82(12):1493-501.
  • Díez-Pérez A, Naylor KE, Abrahamsen B, Agnusdei D, Brandi ML, Cooper C. International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates. Osteoporos Int. 2017;28(3):767-74.
  • Naylor KE, Jacques RM, Paggiosi M, Gossiel F, Peel NF, McCloskey EV. Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study. Osteoporos Int. 2016;27(1):21-31.
  • Camacho PM, Petak SM, Binkley N, Clarke BL, Harris ST, Hurley DL. American Association of Clinical Endocrinologists and American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis 2016. Endocr Pract. 2016;22(Suppl 4):1-42.
  • Qaseem A, Forciea MA, McLean RM, Denberg TD. Treatment of low bone density or osteoporosis to prevent fractures in men and women: a clinical practice guideline update from the American College of Physicians. Ann Intern Med. 2017;166(11):818-39.
  • McClung MR, Wagman RB, Miller PD, Wang A, Lewiecki EM. Observations following discontinuation of long-term denosumab therapy. Os-teoporos Int. 2017;28(5):1723-32.
  • Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med. 2017;377(15):1417-27.
  • Cosman F, Crittenden DB, Ferrari S, Khan A, Lane NE, Lippuner K7. FRAME study: the foundation effect of building bone with 1 year of romosozumab leads to continued lower fracture risk after transition to denosumab. J Bone Miner Res. 2018;33(7):1219-26.
Data source: Dialnet